Daniel A. Ermann, MD

Had an incredible time filming and participating in this fun discussion with some amazing CLL docs. Check it out!

Dr. @StevenBairMD @CULymphoma contributed to a multicenter study published in @Haematologica about real-world outcomes of lonca in R/R DLBCL. pubmed.ncbi.nlm.nih.gov/39540227/ #lymsm

RW lonca R/R DLBCL outcomes: - 187 pts, 17% bulky, 22% HGBL, 60% prior CAR - ORR 32%, CR 14% (woof), no diff in outcomes if prior CAR - mEFS 2.1 mos, mOS 4.6 mos Dismal outcomes outside of trial setting. #lymsm pubmed.ncbi.nlm.nih.gov/39540227/

Mosun-pola-CHP vs pola-R-CHP 1L DLBCL - 62 pts - mosun arm: CR 73%, 2-yr PFS 71% - pola-R-CHP: CR 77%, 2-yr PFS 82% - more tx d/c in mosun arm No sig benefit of mosun-pola-CHP. #lymsm ashpublications.org/bloodadvances/…

We are excited to have @ErmannMD from @UofUHealth @huntsmancancer, @poh_christina from @fredhutch @UWMedicine and @TravisWiliamsDO from @stlukeshealth talking about #lymphoma at #BTFHemBreast25 in Boise! Join us: education.binayfoundation.org #MedTwitter #MedX #MedEd

Pola outcomes by Hans COO @Eddie_Cliff @dgermain21 #ASH24 - >700 pts in 1L & R/R cohorts - non-GC ORR/CR significantly better in R/R (60% vs 36%), but not 1L cohort - non-GCC PFS (not OS) better in R/R, not 1L - PFS better for non-GC if pola used after (not before) CAR 1/ #lymsm

WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. @timfenske #ASH24

Our @CULymphoma faculty Dr. @StevenBairMD contributed to a multicenter real-world study of loncastuximab in R/R DLBCL in @Haematologica. Outcomes were inferior to those described in clinical trials, with median EFS and OS of 2.1 and 4.6 months. #lymsm pubmed.ncbi.nlm.nih.gov/39540227/

Golcadomide (CELMoD)+RCHOP 1L LBCL @Lymphoma_Doc #ASH24: - randomized 0.2 vs 0.4 mg in dose expansion - 1-yr PFS 85% at 0.4 mg (77% at 0.2) - 90% EOT MRD- at 0.4 (73% at 0.2) - better EOT MRD- with 0.4 mg across high-risk genetics GOLSEEK-1 RCT ongoing with 0.4 mg dose. #lymsm

In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: nej.md/3A00MYS

Congratulations to the 2024 Young Hematology Scholar Awardees! 🏆🩸Thank you for sharing your groundbreaking work and presenting at the #HemeSummit24 this weekend in Nashville! @AkritiC54828 @EmperorBlackMD @FahminB_MDPhD @LopedotePaolo @HannahGoulart @KLChohan @MDAndersonNews @MCIStrong @UICancerCenter @DukeMedSchool @COH_RadOnc @UofUHealth @NorthwesternMed Read more: binayfoundation.org/hematology-sch… #YoungHematologyScholars #HemOnc #Oncology #cancer #medx #meded #OncoDaily

Interested in joining an awesome and collaborative Lymphoma team as a pharmacist? We're hiring! See attached posting. @TischCancer @IcahnMountSinai #application-form" target="_blank" rel="nofollow noopener">careers.accp.com/job/2155343/cl…

New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer

New frontiers in r/r CLL: Dr. Daniel Ermann explores pirtobrutinib and CAR-T therapy. Key points on efficacy, toxicity, and patient selection. How will these options impact your treatment decisions? bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer

New options for relapsed/refractory chronic lymphocytic leukemia: pirtobrutinib and CAR-T Therapy. Dr. Daniel Ermann discusses the latest treatment advancements and key considerations. bit.ly/3YiAlHD #CLLSM @ErmannMD @UofUHealth @huntsmancancer

Important new #CLL news PFS advantage for Acala-Ven+/-Obin vs ICT in 1L CLL. astrazeneca.com/media-centre/p…

Healthcare providers: Our partner, Patient Empowerment Network (PEN), is hosting a webinar addressing optimizing CLL care, with @ChangMDPhD of Emory Healthcare and @ErmannMD of Huntsman Cancer Institute, on Aug. 13 at 1pm ET. Learn more: bit.ly/3Lvy4Bo

Check out @ErmannMD and my new article @ASCO, #ASCODailyNews on Treatment of Richter Transformation. @TischCancer -Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring a Personalized Approach dailynews.ascopubs.org/do/richter-tra…

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma ashpublications.org/blood/article-…

Data on patient outcomes for individuals with #CLL who are >80 is limited due to their underrepresentation in clinical trials. This study used information from the Mayo Clinic CLL Database to analyze how this population responds to treatment for CLL. bit.ly/46xNrSz